{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:21Z","timestamp":1790806821078,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z191100007619041"],"award-info":[{"award-number":["Z191100007619041"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To compare the efficacies and treatment outcomes of intravitreal anti-VEGF agents and laser therapy in retinopathy of prematurity (ROP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective, non-randomized, comparative study of patients diagnosed with type 1 ROP or aggressive posterior ROP (A-ROP) treated with intravitreal anti-VEGF agents or laser therapy as primary treatment at the People's Hospital of Peking University.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,627 eyes of 862 patients were included. In <jats:bold>Group 1<\/jats:bold>, 399 eyes of 204 patients were diagnosed with A-ROP or zone I type 1 ROP. The initial regression of the anti-VEGF subgroup was better than that of the laser subgroup, and the reactivation rate and rate of progression to retinal detachment were lower than those of the laser subgroup. In <jats:bold>Group 2<\/jats:bold>, 1,228 eyes of 658 patients were diagnosed with zone II type 1 ROP. The reactivation rate of the laser subgroup was lower than that of the anti-VEGF subgroup. No significant differences were found in the initial regression and the probability of developing retinal detachment. Among the anti-VEGF agents, the reactivation rate in eyes treated with conbercept was much lower than that in eyes treated with ranibizumab. The spherical power and spherical equivalents of eyes treated with laser were significantly higher than those of eyes treated with anti-VEGF agents 1 year after initial treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In contrast to laser therapy, anti-VEGF agents as primary treatments have potential advantages for eyes with zone I type 1 ROP and A-ROP. For eyes with zone II type 1 ROP, laser photocoagulation and anti-VEGF agents therapy showed similar efficacy; however, the rate of reactivation with laser therapy was significantly lower than that with anti-VEGF agents. Among the anti-VEGF agents, the reactivation rate was much lower in eyes treated with conbercept than in eyes treated with ranibizumab. Compared to anti-VEGF agents, laser treated eyes had greater trend to myopia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.911095","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T05:12:21Z","timestamp":1653973941000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China"],"prefix":"10.3389","volume":"9","author":[{"given":"Dandan","family":"Linghu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2009.04.018","article-title":"Incidence of retinopathy of prematurity in the United States: 1997 through 2005","volume":"148","author":"Lad","year":"2009","journal-title":"Am J Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity","volume":"30","author":"Drenser","year":"2010","journal-title":"Retina"},{"key":"B3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ceo.12280","article-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","volume":"42","author":"Gunn","year":"2014","journal-title":"Clin Exp Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0161-6420(86)33550-4","article-title":"Long-term results of cryotherapy for active stages of retinopathy of prematurity","volume":"93","author":"Ben-Sira","year":"1986","journal-title":"Ophthalmology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0161-6420(85)33918-0","article-title":"Management of retinopathy of prematurity","volume":"92","author":"Tasman","year":"1985","journal-title":"Ophthalmology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF02143053","article-title":"A pilot study on cryotherapy and active retinopathy of prematurity","volume":"224","author":"Tasman","year":"1986","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0161-6420(86)33680-7","article-title":"Cryotherapy for active retinopathy of prematurity","volume":"93","author":"Tasman","year":"1986","journal-title":"Ophthalmology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF02482615","article-title":"Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP)","volume":"74","author":"Palmer","year":"1990","journal-title":"Doc Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/archopht.1994.01090140028007","article-title":"Laser therapy for retinopathy of prematurity","volume":"112","year":"1994","journal-title":"Arch Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/eye.1994.100","article-title":"Indirect diode laser treatment for stage 3 retinopathy of prematurity","volume":"8","author":"Clark","year":"1994","journal-title":"Eye."},{"key":"B14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0161-6420(93)31664-7","article-title":"Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study","volume":"100","author":"Hunter","year":"1993","journal-title":"Ophthalmology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0161-6420(91)32247-4","article-title":"Laser photocoagulation for stage 3+ retinopathy of prematurity","volume":"98","author":"McNamara","year":"1991","journal-title":"Ophthalmology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0161-6420(97)30034-7","article-title":"Early treatment of posterior retinopathy of prematurity: a controlled trial","volume":"104","author":"Vander","year":"1997","journal-title":"Ophthalmology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina."},{"key":"B20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"B21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12886-015-0001-7","article-title":"Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease","volume":"15","author":"Menke","year":"2015","journal-title":"BMC Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.2147\/OPTH.S90979","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity","volume":"9","author":"Arambulo","year":"2015","journal-title":"Clin Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina."},{"key":"B27","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1038\/s41598-018-28987-6","article-title":"A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e70544","DOI":"10.1371\/journal.pone.0070544","article-title":"Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"key":"B29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","article-title":"A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration","volume":"118","author":"Zhang","year":"2011","journal-title":"Ophthalmology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.911095\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T05:12:23Z","timestamp":1653973943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.911095\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":29,"alternative-id":["10.3389\/fmed.2022.911095"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.911095","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"911095"}}